See more : Groupe CRIT SA (CEN.PA) Income Statement Analysis – Financial Results
Complete financial analysis of Amicus Therapeutics, Inc. (FOLD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Amicus Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Garo Aktiebolag (publ) (0REY.L) Income Statement Analysis – Financial Results
- Adimmune Corporation (4142.TW) Income Statement Analysis – Financial Results
- The Yumy Candy Company Inc. (FVGCF) Income Statement Analysis – Financial Results
- Regions Financial Corporation (RN70.F) Income Statement Analysis – Financial Results
- Agrico Acquisition Corp. (RICOU) Income Statement Analysis – Financial Results
Amicus Therapeutics, Inc. (FOLD)
About Amicus Therapeutics, Inc.
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 399.36M | 329.23M | 305.51M | 260.89M | 182.24M | 91.25M | 36.93M | 4.96M | 0.00 | 1.22M | 363.00K | 18.41M | 21.43M | 922.00K | 64.36M | 14.97M | 1.78M | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 37.33M | 38.60M | 34.47M | 31.04M | 21.96M | 14.40M | 6.24M | 833.00K | 1.83M | 0.00 | 13.49M | 20.38M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 362.03M | 290.63M | 271.05M | 229.84M | 160.27M | 76.84M | 30.69M | 4.13M | -1.83M | 1.22M | -13.13M | -1.97M | 21.43M | 922.00K | 64.36M | 14.97M | 1.78M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 90.65% | 88.28% | 88.72% | 88.10% | 87.95% | 84.21% | 83.11% | 83.20% | 0.00% | 100.00% | -3,616.80% | -10.68% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 152.38M | 276.68M | 272.05M | 308.44M | 286.38M | 270.90M | 149.31M | 104.79M | 76.94M | 47.62M | 41.94M | 50.27M | 50.86M | 39.04M | 48.08M | 37.76M | 31.07M | 33.63M | 13.65M | 0.00 | 4.43M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 127.20M | 0.00 | 71.15M | 47.27M | 20.72M | 18.89M | 19.36M | 19.88M | 15.66M | 19.97M | 19.67M | 15.28M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 275.27M | 213.04M | 192.71M | 156.41M | 169.86M | 127.20M | 88.67M | 71.15M | 47.27M | 20.72M | 18.89M | 19.36M | 19.88M | 15.66M | 19.97M | 19.67M | 15.28M | 12.28M | 6.88M | 0.00 | 0.00 |
| Other Expenses | 0.00 | 5.34M | 6.21M | 8.85M | 4.78M | -5.63M | 6.01M | -4.79M | -80.00K | -77.00K | 1.72M | 21.00K | 1.59M | 2.06M | 2.13M | 1.49M | 1.24M | 0.00 | 0.00 | -8.81M | 0.00 |
| Operating Expenses | 427.65M | 495.06M | 470.97M | 473.70M | 461.01M | 402.32M | 241.57M | 179.19M | 126.05M | 69.89M | 62.56M | 71.34M | 72.32M | 56.76M | 70.19M | 58.92M | 47.59M | 46.86M | 20.83M | -8.81M | 6.60M |
| Cost & Expenses | 472.85M | 533.66M | 505.43M | 504.74M | 482.98M | 416.72M | 247.81M | 180.02M | 126.05M | 69.89M | 62.56M | 71.34M | 72.32M | 56.76M | 70.19M | 58.92M | 47.59M | 46.86M | 20.83M | -8.81M | 6.60M |
| Interest Income | 7.08M | 3.02M | 509.00K | 3.23M | 10.25M | 10.46M | 4.10M | 1.60M | 929.00K | 223.00K | 174.00K | 316.00K | 160.00K | 156.00K | 997.00K | 4.82M | 0.00 | 1.99M | 609.52K | 0.00 | 5.00K |
| Interest Expense | 50.15M | 37.12M | 32.47M | 22.43M | 18.87M | 22.40M | 17.24M | 5.40M | 1.58M | 1.48M | 46.00K | 89.00K | 148.00K | 260.00K | 278.00K | 218.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 7.87M | 5.34M | 6.21M | 8.85M | 4.78M | 4.22M | 3.59M | 3.24M | 1.83M | 1.55M | 1.72M | 1.71M | 1.59M | 2.06M | 2.13M | 1.49M | 1.24M | 952.45K | 667.38K | 0.00 | 132.00K |
| EBITDA | -92.08M | -199.58M | -202.87M | -242.98M | -332.26M | -322.47M | -428.29M | -195.14M | -128.71M | -67.01M | -61.38M | -50.24M | -46.54M | -53.76M | -4.16M | -37.64M | -44.57M | -44.70M | -20.20M | -8.81M | -6.47M |
| EBITDA Ratio | -23.06% | -58.28% | -64.19% | -89.14% | -180.52% | -346.79% | -533.94% | -3,529.85% | 0.00% | -5,471.49% | -16,611.57% | -276.41% | -229.27% | -5,816.05% | -4.19% | -283.71% | -2,489.85% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -73.49M | -204.43M | -199.92M | -243.85M | -300.74M | -328.78M | -441.99M | -181.89M | -130.44M | -68.70M | -64.18M | -52.93M | -50.89M | -55.84M | -7.35M | -43.96M | -45.81M | -46.86M | -20.83M | -8.81M | -6.60M |
| Operating Income Ratio | -18.40% | -62.09% | -65.44% | -93.47% | -165.03% | -360.32% | -1,196.82% | -3,668.62% | 0.00% | -5,612.83% | -17,680.72% | -287.50% | -237.41% | -6,056.18% | -11.42% | -293.69% | -2,567.54% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -76.61M | -37.61M | -41.63M | -30.40M | -55.17M | -23.61M | -7.14M | -21.89M | -6.07M | -1.34M | 1.04M | 901.00K | 2.85M | -237.00K | 783.00K | 4.60M | 4.64M | 514.36K | 247.27K | 0.00 | -168.00K |
| Income Before Tax | -150.10M | -242.04M | -241.55M | -274.25M | -355.91M | -349.09M | -449.12M | -203.78M | -132.12M | -70.04M | -63.15M | -52.03M | -48.04M | -56.08M | -6.57M | -39.36M | -41.17M | -46.34M | -20.58M | 0.00 | -6.77M |
| Income Before Tax Ratio | -37.59% | -73.52% | -79.06% | -105.12% | -195.30% | -382.58% | -1,216.14% | -4,110.15% | 0.00% | -5,722.14% | -17,395.32% | -282.60% | -224.13% | -6,081.89% | -10.20% | -262.95% | -2,307.57% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 1.48M | -5.47M | 8.91M | 2.60M | 478.00K | -94.00K | -165.12M | -3.74M | 1.50M | -1.11M | -3.51M | -3.25M | -3.63M | -1.14M | 278.00K | 0.00 | 351.00K | -514.36K | -611.80K | 8.81M | 0.00 |
| Net Income | -151.58M | -236.57M | -250.46M | -276.85M | -356.39M | -349.00M | -284.00M | -200.04M | -132.12M | -68.93M | -59.63M | -48.79M | -44.41M | -54.94M | -6.57M | -39.36M | -41.17M | -46.34M | -19.97M | -8.81M | -6.77M |
| Net Income Ratio | -37.96% | -71.85% | -81.98% | -106.12% | -195.56% | -382.48% | -769.03% | -4,034.73% | 0.00% | -5,631.21% | -16,427.82% | -264.98% | -207.20% | -5,958.35% | -10.20% | -262.95% | -2,307.57% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.51 | -0.82 | -0.92 | -1.07 | -1.48 | -1.88 | -1.85 | -1.49 | -1.20 | -0.93 | -1.16 | -1.07 | -1.28 | -1.98 | -0.29 | -1.75 | -3.11 | -62.97 | -48.69 | -28.64 | -22.01 |
| EPS Diluted | -0.51 | -0.82 | -0.92 | -1.07 | -1.48 | -1.88 | -1.85 | -1.49 | -1.20 | -0.93 | -1.16 | -1.07 | -1.28 | -1.98 | -0.29 | -1.75 | -3.11 | -62.97 | -48.69 | -28.64 | -22.01 |
| Weighted Avg Shares Out | 295.16M | 289.06M | 271.42M | 258.87M | 240.42M | 185.79M | 153.36M | 134.40M | 109.92M | 74.44M | 51.29M | 45.57M | 34.57M | 27.73M | 22.62M | 22.49M | 13.24M | 735.97K | 410.22K | 307.54K | 307.54K |
| Weighted Avg Shares Out (Dil) | 295.16M | 289.06M | 271.42M | 258.87M | 240.42M | 185.79M | 153.36M | 134.40M | 109.92M | 74.44M | 51.29M | 45.57M | 34.57M | 27.73M | 22.62M | 22.49M | 13.24M | 735.97K | 410.22K | 307.54K | 307.54K |
Amicus Therapeutics Issues 2024 Environmental, Social, and Governance (ESG) Report
PRINCETON, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today issued its fourth annual Environmental, Social, and Governance (ESG) report. This year's...
Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2024
PRINCETON, N.J., March 01, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in March.
Amicus' (FOLD) Q4 Earnings Beat, Revenues Meet Estimates
Amicus' (FOLD) fourth-quarter earnings beat estimates while revenues meet the same. Stock down.
Amicus Therapeutics: Expect Improved Commercial Momentum In 2024
Amicus Therapeutics should deliver strong topline growth with expanding margins and increasing cash flows in 2024.
Amicus Therapeutics, Inc. (FOLD) Q4 2023 Earnings Call Transcript
Amicus Therapeutics, Inc. (FOLD) Q4 2023 Earnings Call Transcript
Amicus Therapeutics (FOLD) Reports Q4 Loss, Lags Revenue Estimates
Amicus Therapeutics (FOLD) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to loss of $0.19 per share a year ago.
Amicus Therapeutics Announces Full-Year 2023 Financial Results and Corporate Updates
2023 Total Revenue of $399.4M, a 21% Increase Year-over-Year Strong Patient Demand Continues for Pombiliti ™ + Opfolda ™ in the U.S., U.K., and Germany Projecting 2024 Galafold ® Revenue Growth of 11-16% at CER Anticipating Full-Year Non-GAAP Profitability in...
Amicus Therapeutics to Announce Full Year 2023 Financial Results on February 28, 2024
PRINCETON, N.J., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, February 28, 2024, at 8:30 a.m. ET to discuss financial results for...
Amicus Therapeutics Receives the 2024 New Treatment Award for Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) at the 20th Annual WORLDSymposium™
- Award Recognizes Approval of Amicus Therapeutics' Two-component Therapy for the Treatment of Late-onset Pompe Disease - - Award Recognizes Approval of Amicus Therapeutics' Two-component Therapy for the Treatment of Late-onset Pompe Disease -
Amicus Therapeutics Announces Presentations and Posters at the 20th Annual WORLDSymposium™ 2024
PRINCETON, N.J., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that one oral presentation and 11 posters across its development programs will be included at the 20th Annual WORLDSymposium™ 2024, being held February 4-9, 2024 in...
Source: https://incomestatements.info
Category: Stock Reports